



**TAYSIDE MEDICAL SCIENCE CENTRE POLICY**  
**SELECTION AND OVERSIGHT OF VENDORS FOR CLINICAL TRIALS OF INVESTIGATIONAL**  
**MEDICINAL PRODUCTS (CTIMPs)**

POLICY NUMBER:	TASC POLICY 012 v3
AUTHOR:	Valerie Godfrey
EFFECTIVE DATE:	05 Aug 2025
REVIEW DATE:	05 Aug 2027

### **Third Party/Vendor definition**

A third party or vendor is considered to be any organisation or individual (commercial or non-commercial), other than the University of Dundee (UoD) or NHS Tayside (NHST), undertaking agreed duties at the request of the Sponsor where such duties are relating to the Sponsor's responsibilities in relation to a study.

Such duties may include drug and/or medical device suppliers/distributors, archiving providers, laboratory service providers, courier services, transcription services, translation services, statistical analysis and data management providers.

There should also be appropriate vendor oversight processes in place for collaborators who are conducting trial duties on behalf of Sponsor.

Co-sponsors and co-investigators (who are named on grant applications) and collaborators, who are only providing an opinion in relation to a study but not a service, are excluded from the definition of third party/vendor in this policy.

### **Background**

The process of vendor oversight begins with the selection of a suitable vendor which may be initiated by the Chief Investigator (CI). As such, the Sponsor should implement processes for assessing the suitability of a vendor prior to the signing of agreements. These processes will vary depending on the risks associated with the tasks being delegated and what is previously known about the vendor.

Agreements should clearly detail the delegated tasks, duties and functions between the parties, the required standards of service (including Good Clinical Practice [GCP]) and the process for subcontracting work (to ensure that subcontracting does not occur without Sponsor approval). Agreements must be kept current.

Work must not commence until the agreement is signed by all parties.

## **Applicability**

This policy applies to TASC staff, Sponsor, CI and researchers conducting Clinical Trials of an Investigational Medicinal Product (CTIMP) sponsored or co-sponsored by UoD and/or NHS Tayside NHST. The policy should also be considered best practice for any other clinical research project.

## **Selection of vendors**

The CI must inform the Sponsor at the earliest opportunity of any external company or service provider that they wish to engage to deliver the research. The rationale for using and the decision to select a particular vendor will be taken by the CI and Sponsor and shall be subject to the vendor meeting the standards expected for compliance with GCP and UK regulations following the checks made on behalf of Sponsor.

When the CI engages vendor services via UoD, the CI must follow the UoD Procurement Policy. When the CI engages vendor services via NHST, the appropriate NHST tender process must be followed.

Vendors may be 'Known' or 'Unknown' to TASC. 'Known' is defined as any company or service provider used previously by TASC and deemed acceptable. 'Unknown' is defined as any company or service provider that is new to TASC and requires a vendor assessment. If circumstances have changed considerably, a 'Known' vendor may require to be re-assessed. TASC Legal will keep a list of vendors who have been used and/or assessed during the last 10 years.

## **Vendor assessment**

Unless the vendor is 'Known' and acceptable, then TASC Quality Assurance (QA) and TASC Legal will begin a process for assessing vendor suitability. The level of checks will be proportionate to the study and service that will be provided and risks involved. If technical expert advice is required, support from appropriately qualified members of staff in UoD and NHST will be requested.

If TASC Legal and TASC QA are satisfied with the vendor, then TASC Legal will add the vendor's name to TASC Legal's list of acceptable vendors. If there are any issues with the vendor, then TASC Research Governance will be informed of the specific issue(s).

The CI or delegate is responsible for ensuring that vendors are provided with all the appropriate documentation (including updates) to enable them to perform their agreed activities.

The Sponsor retains the right to decline the use of a proposed vendor. Where an unfavourable review leads to a decision resulting in non-acceptance by the Sponsor, the CI will be informed and the vendor will be advised of the rejection by the CI.

## Oversight of vendors

The CI shall maintain regular contact with the third party/parties.  
After Sponsorship Approval, any additional vendor or change of vendor will be reported to TASC Research Governance by the CI so that vendor assessment can be carried out if required (in accordance with the criteria above). The Research Governance Manager shall also advise whether a protocol amendment is required.

Any significant issues arising in connection with potential or current vendors must be escalated to TASC Research Governance and/or TASC R&D Director.

TASC QA will carry out audits as scheduled and/or vendor assessments upon request by the Sponsor.

Annual review of TASC's Legal vendor list will be carried out by TASC QA, TASC Legal and TASC Research Governance. Updates and adjustments to the list will be made as required.

## ABBREVIATIONS

CI	Chief Investigator
CTIMP	Clinical Trial of an Investigational Medicinal Product
GCP	Good Clinical Practice
NHST	NHS Tayside
QA	Quality Assurance
RG	Research Governance
TASC	Tayside Medical Science Centre
UoD	University of Dundee

## DOCUMENT HISTORY

*History prior to 2021 is in the archived Policies available from TASC Quality Assurance Dept.*

Version Number:	Reviewed By (Job Title):	Effective Date:	Details of editions made:
1	Valerie Godfrey (TASC QA Manager)	02/08/2021	New.
2	Valerie Godfrey (TASC QA Manager)	02/08/2023	Title changed from Clinical Research to CTIMPs. Page 2, Vendor assessment section, has been updated. Appendix 1 (Vendor Checklist) has been removed.
3	Valerie Godfrey (TASC QA Manager)	05/08/2025	Removal of sentence on page 2 that states that TASC QA will file evidence of checks by TASC Legal "Contract" has been changed to "Agreement" in line with new ICH-GCP R3 vocabulary.

**APPROVALS**

<b>Approved by:</b>	<b>Date:</b>
Professor Linda Martindale, Dean, School of Health Sciences, University of Dundee, on behalf of TASC Research Governance and Oversight Committee	30 July 2025
<b>Approved by:</b>	<b>Date:</b>
Dr Steve McSwiggan, Senior R&D Manager NHS Tayside	05 Aug 2025